<img src="https://ml.globenewswire.com/Resource/Download/a88cd5f5-0b05-416c-a56b-e4130c10cfca?size=2" nborder="0" align="left" hspace="5" vspace="5" title="New taysha_inline_fullcolor_rgb_12in@300ppi.jpg" alt="Taysha Gene Therapies, Inc."/>DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2026, and host a corporate update conference call and webcast on Tuesday, August 11, 2026, at 4:30 PM Eastern Time. Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha’s website at <a href="https://www.globenewswire.com/Tracker?data=VO5BJ-Jat7QlmcZeTzSO8LeGw9_dQub6AVuhQvOWJrpZ66kViCJ0yq8uH5w0skDmq_AmCZu5JFX2xfipbsONOGsTzq_ZYbt7yFS2DxD1f73gS5CWUkTHSiCjcv7YiisMjWOUrL2B9SeYTSJ0N-E4sA==" rel="nofollow" target="_blank" title="ir.tayshagtx.com">ir.tayshagtx.com</a>. An archived replay of the webcast will be available on the Company’s website. About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=QcEzg49rzsv74OsqvF-vO1SBhHIcIuCedHql-LeWaJMcu9j_H_IBbwzN2okQ7aQy1LOvstbrXMFl5J50aVCeL4KgpadjKHsT9Kc-ldJyN_A=" rel="nofollow" target="_blank" title="www.tayshagtx.com">www.tayshagtx.com</a>. Company Contact: Hayleigh Collins Senior Director, Corporate Communications and Investor Relations Taysha Gene Therapies, Inc. <a href="https://www.globenewswire.com/Tracker?data=yX6r8pPhUvryrgsycbsqqLtXhcelKeRT0Q-ngdoBsdJHG9hhsz0Zpkmujjtyge4e1t9vlXYAiNZB9oBHzlzwAg6NYfaaoimasIVp0eqBFx0=" rel="nofollow" target="_blank" title="hcollins@tayshagtx.com">hcollins@tayshagtx.com</a>  Media Contact: <a href="https://www.globenewswire.com/Tracker?data=gNeGaaferTz_tWYtHR9oRyfXZO4Eoslk-voIxDNMX1sV5niTeoYCpBTsU0NcNPQvE9N0nJKbzcQVmuPKfxApwK7gYvXoLgoenT_5mH4a6AU=" rel="nofollow" target="_blank" title="media@tayshagtx.com">media@tayshagtx.com</a> <img alt="" src='https://ml.globenewswire.com/media/OGVhMWYxNGUtYzc2Ny00YzhkLWE0OTgtMzgzZTdkMDFhNDYyLTEyMTM5NjYtMjAyNi0wOC0wNC1lbg==/tiny/Taysha-Gene-Therapies-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn